Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease.
Lennart PhilippenNatalie SchubAndreas GüntherGunnar CarioMartin SchrappeRoland ReppMartin GramatzkiPublished in: Bone marrow transplantation (2023)